Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Malaria
Interventions
DRUG

Coartem

"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."

Trial Locations (2)

113

Centre de Recherches Médicales de Ngounié, Fougamou

118

Centre de Recherches Médicales de Lambaréné, Hôpital Albert Schweitzer, Lambaréné

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

Albert Schweitzer Hospital

OTHER

NCT02528279 - Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria | Biotech Hunter | Biotech Hunter